XML 77 R48.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Note 10 - Commitments and Contingencies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands |  |  | 12 Months Ended
--- | --- | --- | ---
Mar. 14, 2017 | Feb. 02, 2015 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015
Operating Leases, Rent Expense, Net |  |  | $ 200 | $ 136 | $ 33
Research and Development Expenses Settled by Shares Issuance |  |  | $ 42,259 |  |
Shares Issued, Price Per Share | $ 20 |  |  |  |
Private Placement [Member] | Nereus Trust [Member] |  |  |  |  |
Stock Issued in Lieu of Royalty Payments | 2,112,963 |  |  |  |
Wanchun Biotech [Member] |  |  |  |  |
Quarterly Royalty Payments Required As a Percentage of Gross Proceeds on Sale of Product |  |  | 20.00% |  |
Term of Royalty Payments |  |  | 10 years |  |
Wanchun Biotech and Fortis Advisors LLC [Member] |  |  |  |  |
Period Following Royalty Termination Agreement, Requirement to Issue Shares |  | 3 years |  |  |
Percentage of Fully-diluted Equity Capitalization Required to Be Issued As Shares in Lieu of Royalty Payments |  | 10.00% |  |  |

X
- Definition The percent of the fully-diluted equity capitalization of the Company required to be issued as shares in lieu of royalty payments. + References No definition available. + Details
Name: | bysi_PercentageOfFullyDilutedEquityCapitalizationRequiredToBeIssuedAsSharesInLieuOfRoyaltyPayments
Namespace Prefix: | bysi_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The requirement to issue shares in lieu of royalty payments if the Company offers an IPO within this time frame. + References No definition available. + Details
Name: | bysi_PeriodFollowingRoyaltyTerminationAgreementRequirementToIssueShares
Namespace Prefix: | bysi_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percent of gross proceeds from the sale of product that is required to be paid out as royalties on a quarterly basis. + References No definition available. + Details
Name: | bysi_QuarterlyRoyaltyPaymentsRequiredAsAPercentageOfGrossProceedsOnSaleOfProduct
Namespace Prefix: | bysi_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the amount of research and development expense related to patent acquired settled by shares issuance. + References No definition available. + Details
Name: | bysi_ResearchAndDevelopmentExpensesSettledBySharesIssuance
Namespace Prefix: | bysi_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued in lieu of royalty payments. + References No definition available. + Details
Name: | bysi_StockIssuedInLieuOfRoyaltyPayments
Namespace Prefix: | bysi_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The term in which royalty payments are due. + References No definition available. + Details
Name: | bysi_TermOfRoyaltyPayments
Namespace Prefix: | bysi_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717 + Details
Name: | us-gaap_OperatingLeasesRentExpenseNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=bysi_NereusTrustMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bysi_WanchunBiotechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bysi_WanchunBiotechAndFortisAdvisorsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |